Tiziana Life Sciences Ltd (TLSA) Stock

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has dosed the first patient with moderate Alzheimer's disease with its lead investigational drug candidate intranasal foralumab. The company said this milestone took place at Brigham and Women's Hospital in Boston as part of a study aimed at addressing neuroinflammation, a key factor in Alzheimer's progression.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to additional trial sites across the Northeast of the United States. The trial sites include highly-regarded institutions, including Yale University, Johns Hopkins University, Cornell University, University of Buffalo, University of Massachusetts, and Thomas Jefferson University.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its grant application to the ALS Association has been approved. The company has secured funding under the Hoffman ALS Clinical Trial Awards Program which will be used for a 20-patient study investigating the safety and early efficacy of its investigational drug intranasal foralumab in patients with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. CEO Ivor Elrifi joined Proactive to discuss the findings.

Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured a $4 million grant from the National Institutes of Health (NIH) to advance research of nasal anti-CD3 as a treatment for Alzheimer's disease. The company has been developing a fully human, anti-CD3 monoclonal antibody called intranasal foramulab, which has demonstrated a favorable safety profile and clinical response in studies to date.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that foralumab is the only fully human anti-CD3 monoclonal antibody (mAb), which binds to the T cell receptor and dampens inflammation by modulating T cell function, therefore suppressing effector features in multiple immune cell subsets.

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's disease with its investigational therapeutic intranasal foralumab. Expanded access INDs allow patients to gain access to investigational drugs, biologics and medical devices to treat serious diseases and conditions for which there are no comparable or satisfactory therapy options outside of clinical trials, the biopharmaceutical company said.